Biomea Fusion Inc.
Biomea Fusion is a precision oncology and diabetes-focused biotechnology company dedicated to developing innovative covalent small molecule therapies. Their mission is to revolutionize medicine by creating therapies that cure patients of their disease, leveraging their drug design and operational expertise to produce highly selective, targeted medicines. They have built an R&D engine that has produced multiple programs in preclinical and clinical development, including covalent inhibitors targeting key mechanisms of disease. The company aims to deliver impactful treatments swiftly and has a portfolio targeting specific gene alterations involved in tumor growth and diabetes. Their research emphasizes the role of menin in diabetes, particularly in beta-cell proliferation and regeneration, aiming to restore pancreatic function and insulin sensitivity. They focus on subgroup-specific treatments for type 2 diabetes, especially severe insulin-deficient cases, with promising clinical data from studies like COVALENT-111. The company also explores the potential of covalent drugs in oncology, targeting proteins involved in cancer progression. Their pipeline includes covalent inhibitors like icovamenib, designed to promote beta-cell regeneration, improve glycemic control, and potentially prevent or treat diabetes and related metabolic diseases.
Industries
Nr. of Employees
medium (51-250)
Biomea Fusion Inc.
Patents
Crystalline forms of N[4[4-(4-Morpholinyl)-7H-Pyrrolo[2-3-D]Pyrimidin-6-yl]Phenyl]-4-[[3(R)-[(1-Oxo-2-Protein-1-yl)Amino]-1-Piperidinyl]Methyl]2-Pyridinecarboxamide]
US-12215113-B2
View DetailsCrystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction
US-12018032-B2
View Details
Crystalline forms of N[4[4-(4-Morpholinyl)-7H-Pyrrolo[2-3-D]Pyrimidin-6-yl]Phenyl]-4-[[3(R)-[(1-Oxo-2-Protein-1-yl)Amino]-1-Piperidinyl]Methyl]2-Pyridinecarboxamide]
US-12215113-B2
View DetailsCrystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction
US-12018032-B2
View DetailsProducts
BMF-219
An oral investigational covalent menin inhibitor targeting genetically defined cancers such as AML, ALL, DLBCL, MM, and CLL, as well as type 2 diabetes by enabling beta-cell proliferation and function.
FUSION™ System
A proprietary platform for designing and developing novel covalent small molecule therapies targeting high-value genetic drivers of cancer and metabolic diseases.
BMF-500
An investigational, orally bioavailable, highly potent and selective covalent small molecule inhibitor of FLT3, designed for treating AML and potentially in combination with other therapies.
BMF-219
An oral investigational covalent menin inhibitor targeting genetically defined cancers such as AML, ALL, DLBCL, MM, and CLL, as well as type 2 diabetes by enabling beta-cell proliferation and function.
FUSION™ System
A proprietary platform for designing and developing novel covalent small molecule therapies targeting high-value genetic drivers of cancer and metabolic diseases.
BMF-500
An investigational, orally bioavailable, highly potent and selective covalent small molecule inhibitor of FLT3, designed for treating AML and potentially in combination with other therapies.